For Whom the Trial is Intended?
The VIABLE clinical trial is intended for patients with metastatic castration‐resistant prostate cancer who have not yet received chemotherapy (see the section entitled Prostate Cancer). Patients must meet the entry criteria defined in the protocol in order to participate.
Participating in a clinical trial is entirely voluntary. Before receiving any study treatment or undergoing any study procedures, eligible patients must agree to participate in the study by signing an Informed Consent Form (ICF). An Informed Consent Form explains in plain language the study design, the treatment, the procedures involved, and of the known potential risks and benefits of participating. Patients should be given time to read the consent form and ask questions. Patients should fully understand the details of participation before signing the form. Even after signing the ICF, a person on a clinical trial is free to change his/her mind and leave the study at any time. A person who participates on a clinical trial is referred to as a study subject.